The goal of this clinical trial is to compare the effects of Full-Spectrum CBD (CBD containing a small amount of THC), Broad-Spectrum CBD (CBD with no THC), and placebo on alcohol consumption and clinically relevant Alcohol Use Disorder (AUD) phenotypes among adults with AUD. The main questions it aims to answer are:
* Does Full-Spectrum CBD (fs-CBD), compared to Broad-Spectrum CBD (bs-CBD) and placebo, reduce participant alcohol consumption?
* Does Full-Spectrum CBD (fs-CBD), compared to Broad-Spectrum CBD (bs-CBD) and placebo, reduce negative emotionality and other AUD phenotypes?
* What are the effects of fs-CBD and bs-CBD on the gut microbiome and gut permeability?
Researchers will compare fs-CBD to bs-CBD and a placebo (a look-alike substance that contains no CBD or THC) to see if fs-CBD reduces participant alcohol consumption.
Participation will last 12 weeks during which participants will:
* Take the randomly assigned study drug (fs-CBD, bs-CBD, or placebo) daily for 8 weeks and report alcohol use via daily surveys
* Attend 5 in-person study visits
* Check in virtually with study staff weekly during the 8-week medication period
Phase:
PHASE2
Details
Lead Sponsor:
University of Colorado, Denver
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)